News Daily News Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis Todd Neale August 13, 2025
News Daily News Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments Michael O'Riordan January 03, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2024 Shelley Wood November 01, 2024
News Opinion Editor's Corner TCT 2024 What’s Going to Be Big at TCT 2024? Michael O'Riordan October 17, 2024
News Daily News ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI Michael O'Riordan July 01, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2024 Shelley Wood May 31, 2024
News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2023 Shelley Wood November 30, 2023
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Conference News EuroPCR 2023 Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization Michael O'Riordan May 19, 2023
News Daily News COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK Michael O'Riordan September 15, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022
News Conference News EuroPCR 2021 Elective Revascularization, Better Long-term Survival: Meta-analysis Michael O'Riordan May 18, 2021